Table 1

Weeks 16* and 52 efficacy endpoints for patients treated continuously with ixekizumab: COAST-V and COAST-W (ITT population: NRI, modified baseline observation carried forward)

COAST-V (bDMARD-naive)COAST-W (TNFi-experienced)
IXE Q4W
(n=81)
IXE Q2W
(n=83)
IXE Q4W
(n=114)
IXE Q2W
(n=98)
Patients achieving response, n (%)
NRI Week 16Week 52Week 16Week 52Week 16Week 52Week 16Week 52
 ASAS4039 (48.1)43 (53.1)43 (51.8)42 (50.6)29 (25.4)39 (34.2)30 (30.6)30 (30.6)
 ASAS2052 (64.2)53 (65.4)57 (68.7)59 (71.1)55 (48.2)60 (52.6)46 (46.9)47 (48.0)
 ASAS partial remission12 (14.8)22 (27.2)12 (14.5)20 (24.1)7 (6.1)13 (11.4)5 (5.1)8 (8.2)
 ASDAS clinically important improvement50 (61.7)51 (63.0)50 (60.2)51 (61.4)51 (44.7)53 (46.5)48 (49.0)44 (44.9)
 ASDAS major improvement24 (29.6)30 (37.0)19 (22.9)29 (34.9)18 (15.8)27 (23.7)21 (21.4)26 (26.5)
 ASDAS <2.1
 (low disease activity)
35 (43.2)43 (53.1)35 (42.2)43 (51.8)20 (17.5)27 (23.7)16 (16.3)24 (24.5)
 ASDAS <1.3
 (inactive disease)
13 (16.0)18 (22.2)9 (10.8)16 (19.3)4 (3.5)10 (8.8)5 (5.1)4 (4.1)
 BASDAI5034 (42.0)40 (49.4)36 (43.4)37 (44.6)25 (21.9)31 (27.2)23 (23.5)27 (27.6)
Mean change from baseline (SD)
mBOCFWeek 16Week 52Week 16Week 52Week 16Week 52Week 16Week 52
 ASDAS−1.4 (1.2)−1.6 (1.1)−1.4 (1.0)−1.6 (1.0)−1.1 (1.0)−1.2 (1.1)−1.2 (1.1)−1.3 (1.2)
 BASDAI−3.0 (2.4)−3.3 (2.5)−2.7 (2.1)−3.1 (2.3)−2.1 (2.0)−2.4 (2.4)−2.1 (2.3)−2.4 (2.3)
 BASFI−2.4 (2.3)−2.8 (2.5)−2.5 (2.2)−2.8 (2.4)−1.6 (2.1)−2.1 (2.5)−1.9 (2.3)−2.1 (2.3)
 SF-36 PCS‡7.6 (8.4)8.3 (9.5)7.8 (7.0)8.1 (7.5)6.3 (7.5)6.5 (8.5)6.0 (7.7)7.1 (7.6)
 ASAS Health Index−2.3 (3.3)−2.7 (3.3)−2.8 (3.2)−3.3 (3.6)−2.0 (3.1)−2.3 (3.7)−1.8 (3.9)−2.5 (3.5)
 SPARCC MRI spine score§−8.9 (16.2)−8.8 (17.3)−8.7 (16.5)−8.5 (15.9)−3.2 (8.3)NA−5.1 (11.9)NA
 SPARCC MRI sacroiliac joint score¶−3.4 (7.6)−3.3 (8.7)−4.1 (7.3)−4.2 (7.5)NANANANA
 CRP, mg/L−6.8 (16.7)−9.2 (12.4)−8.4 (15.7)−9.6 (14.5)−11.5 (30.1)−10.4 (31.1)−10.3 (19.3)−10.0 (18.5)
  • *Except for ASAS partial remission (both studies), ASDAS clinically important improvement (both studies), ASDAS major improvement (both studies), ASDAS <1.3 (COAST-W) and BASDAI50 (COAST-W), all week 16 data have been previously reported.10 11

  • †For patients who discontinued study drug because of an adverse event, the baseline observation was carried forward to the corresponding time point for evaluation. For patients discontinuing study drug for any other reason, the last non-missing observation before discontinuation was carried forward to the corresponding time point for evaluation.

  • ‡SF-36 PCS data are reported as t-scores, based on 2009 US general population norms.

  • §Observed data only (not assessed after week 16 in COAST-W). COAST-V: week 16, n=78 (IXE Q4W) and n=74 (IXE Q2W); week 52, n=72 (IXE Q4W) and n=68 (IXE Q2W). COAST-W: week 16, n=49 (IXE Q4W) and n=45 (IXE Q2W).

  • ¶Observed data only (not assessed in COAST-W). COAST-V: week 16, n=78 (IXE Q4W) and n=75 (IXE Q2W); week 52, n=72 (IXE Q4W) and n=69 (IXE Q2W).

  • ASAS, Assessment of SpondyloArthritis international Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; bDMARD, biological disease-modifying antirheumatic drug; CRP, C reactive protein; ITT, intent to treat; IXE Q2W, ixekizumab 80 mg every 2 weeks; IXE Q4W, ixekizumab 80 mg every 4 weeks; mBOCF, modified baseline observation carried forward; NA, not applicable; NRI, non-responder imputation; SF-36 PCS, Medical Outcomes Study 36-item Short-Form Health Survey Physical Component Score; SPARCC, Spondyloarthritis Research Consortium of Canada; TNFi, tumour necrosis factor inhibitor.